In February 2026, Vaxcyte reported a full-year 2025 net loss of US$766.63 million and higher loss per share, while also raising roughly US$408.10 million through an at-the-market follow-on equity ...
网页链接In February 2026, Vaxcyte reported a full-year 2025 net loss of US$766.63 million and higher loss per share, while also raising roughly US$408.10 million through an at-the-market follow-on equity ...
网页链接免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。